10.15.13
Sabinsa Corporation, East Windsor, NJ, has been issued a “No Comment” letter from the FDA regarding the determination that the company’s Curcumin C3 Complex is Generally Recognized As Safe (GRAS). Sabinsa’s Curcumin C3 Complex is the only curcumin in the market that has been reviewed and acknowledged by FDA for GRAS status, according to the company.
Curcumin C3 Complex has been self-affirmed GRAS since 2009 after a comprehensive review of safety and toxicology data by an independent panel of scientists of international repute assembled by Soni & Associates, Inc. Dr. Madhu Soni was also instrumental in this FDA GRAS application.
“The ‘no comment’ letter from FDA was the next logical step in Sabinsa’s long history pioneering curcumin’s growth,” said Muhammed Majeed, PhD, Sabinsa’s founder. “With the majority of the published studies on curcumin using C3 Complex, it is no wonder it’s the preferred ingredient on the market. GRAS status expands the pool of products in which it can be used.”
“Since Sabinsa’s Curcumin C3 Complex is a patented, uniquely produced ingredient, this GRAS status does not extend to competitor’s products,” said Reza Kamarei, PhD, Sabinsa’s vice president of science & technology. “This letter applies to only Sabinsa’s product, the way it is manufactured and for its specifications, and others can not copy it. If others need to claim their product is FDA affirmed GRAS, then they will need to submit GRAS notification to FDA.“
GRAS status allows manufacturers additional freedom to add Curcumin C3 Complex in a variety of foods and beverages ranging from baked goods to soups, snack foods, imitation dairy products and seasonings & flavors.
A common spice used in South Asian cooking, turmeric and the component curcuminoids have been preclinically and/or clinically validated for their beneficial role in maintaining health and wellness. The patented, well-characterized Curcumin C3 Complex is the turmeric ingredient selected by numerous scientists in the U.S. and internationally, as the most desirable material to facilitate cutting edge research on curcuminoids. For the latest updates, visit www.curcuminc3complex.com or www.curcuminoids.com
Curcumin C3 Complex has been self-affirmed GRAS since 2009 after a comprehensive review of safety and toxicology data by an independent panel of scientists of international repute assembled by Soni & Associates, Inc. Dr. Madhu Soni was also instrumental in this FDA GRAS application.
“The ‘no comment’ letter from FDA was the next logical step in Sabinsa’s long history pioneering curcumin’s growth,” said Muhammed Majeed, PhD, Sabinsa’s founder. “With the majority of the published studies on curcumin using C3 Complex, it is no wonder it’s the preferred ingredient on the market. GRAS status expands the pool of products in which it can be used.”
“Since Sabinsa’s Curcumin C3 Complex is a patented, uniquely produced ingredient, this GRAS status does not extend to competitor’s products,” said Reza Kamarei, PhD, Sabinsa’s vice president of science & technology. “This letter applies to only Sabinsa’s product, the way it is manufactured and for its specifications, and others can not copy it. If others need to claim their product is FDA affirmed GRAS, then they will need to submit GRAS notification to FDA.“
GRAS status allows manufacturers additional freedom to add Curcumin C3 Complex in a variety of foods and beverages ranging from baked goods to soups, snack foods, imitation dairy products and seasonings & flavors.
A common spice used in South Asian cooking, turmeric and the component curcuminoids have been preclinically and/or clinically validated for their beneficial role in maintaining health and wellness. The patented, well-characterized Curcumin C3 Complex is the turmeric ingredient selected by numerous scientists in the U.S. and internationally, as the most desirable material to facilitate cutting edge research on curcuminoids. For the latest updates, visit www.curcuminc3complex.com or www.curcuminoids.com
